Aspect of adhesives in transdermal drug delivery systems
Source abstract
Abstract
Transdermal drug delivery systems (TDDS), also well-known as “patches,” are the dosage forms designed to deliver a therapeutically effective amount of drug across the skin. The quality attribute of the adhesives in TDDS is indispensible for fabrication design and important to the safety, efficacy and quality evaluation of the final product. Advances in the field of adhesive science have paved the way for designing TDDS that have considerable flexibility. This review article provides a brief idea of adhesives being used in commercially, types of transdermals, their anatomy, fabrication design, assessment of adhesion parameters, regulatory aspects, success and commercial application of adhesive technology in transdermal therapy. This article also provides a framework for past, present and future developments of adhesive based technology in transdermal performance.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Intramuscular injections and effects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (92)
Show source-provided references
1. Transdermal drug delivery: the inherent challenges and technological advancements
2. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute10.1016/j.ejpb.2006.03.009 ↗
3. Biomedical materials10.1002/0471440264.pst551 ↗
4. Polymers in controlled drug delivery
5. Skin adhesives and skin adhesion. Transdermal drug delivery system10.1016/S0142-9612(98)00020-9 ↗
6. Crystallization of β-estradiol in an acrylic transdermal drug delivery system10.1002/(SICI)1097-4636(19990315)44:4<397::AID-JBM5>3.0.CO;2-Q ↗
7. Developing custom adhesive systems for transdermal drug delivery products
8. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization10.1016/j.jfda.2014.01.022 ↗
9. Development and evaluation of a monolithic drug-in-adhesive patch for valsartan10.1016/j.ijpharm.2010.09.031 ↗
10. Optimal process design for the manufacture of transdermal drug delivery systems10.1016/S1461-5347(00)00251-0 ↗
11. Drug delivery systems for challenging molecules
12. Material selection for transdermal delivery systems
13. Adhesives
14. Evaluation of adhesive properties of patches based on acrylic matrices10.1081/DDC-100102135 ↗
15. Transdermal delivery
16. Barnhart S. Critical role of PSAs in transdermal drug delivery; adhesives and sealants industry, 1–6 April; 1998.
17. Pressure-sensitive adhesives for transdermal drug delivery systems
18. Permeation enhancers compatible with transdermal drug delivery systems, Part II: System design considerations
19. Customizing silicone adhesives for transdermal drug delivery systems
20. Design and evaluation of a lorazepam transdermal delivery system10.3109/03639049709149144 ↗
21. Dermal patches for controlled release of miconazole: influence of drug concentration on the technical characteristics10.1081/DDC-100102225 ↗
22. Acrylic ester polymers
23. Burgess · Chem Ind · 1952 · 78
24. X-ray Examination of Polyisobutylene10.1021/ja01865a003 ↗
25. Wood · Rubber Chem Technol · 1976 · 49 · 18910.5254/1.3534955 ↗
26. Takayasu T, Kakubari I, Shinkai N, Kawakami J, Nakajima, N, Uruno A. Patch, US Patent no. 6211425 (assigned to Saitama Daiichi Seiyaku Kabushiki Kaisha [Kasukabe, JP]; 2001).
27. Woodard JT, Metevia VL. Transdermal drug delivery devices with amine-resistant silicone adhesives, US Patent no. 4655767 (assigned to Dow Corning Corporation [Midland, MI]; 1987).
28. Muraoka T, et al. Percutaneous absorption preparation, US Patent no. 6132761 (assigned to Nitto Denko Corporation [Osaka, JP]; 2000).
29. Pretzer PW, Sweet RP. Silicone pressure-sensitive adhesive composition containing functionalized polyisobutylene, US Patent no. 5939477 (assigned to Dow Corning Corporation [Midland, MI]; 1999).
30. Janssen, Duragesic (fentanyl transdermal system) full prescribing information, Titusville, NJ; May 2003.
31. Effect of skin penetration enhancers in transdermal drug delivery adhesives on skin adhesion and irritation
32. Release of chemical penetration enhancers from drug-in-adhesive transdermal patches10.1016/S0378-5173(01)00893-6 ↗
33. Transdermal patches: high risk for error?
34. Polymorphism of 17-β estradiol in a transdermal drug delivery system10.1023/A:1014058817352 ↗
35. Polymers in transdermal drug delivery systems
36. How do specialty polymers modify the chemical and pharmaceutical industries?10.1080/10601329409350097 ↗
37. Gale R, Spitze LA. Permeability of camphor in ethylene-vinyl acetate copolymers. In: Proceedings of the eighth international symposium on controlled release of bioactive materials (Controlled Release Society, Minneapolis, MN; 1981), p. 183.
38. K.J. Godbey, Improving patient comfort with non-occlusive transdermal backings, in American Association of Pharmaceutical Scientists, 1996, 1–2.
39. D. Rolf, U. Sjoblom, K. Elisabeth. Method of forming adhesive patch for applying medication to the skin, U.S. Patent no. 6096333 (assigned to LecTec Corporation [Minnetonka, MN]; 2000).
40. Pharmaceutical development and characteristics of a new glyceryl trinitrate transdermal patch
41. Microbial degradation of polyurethane, polyester polyurethanes and polyether polyurethanes10.1007/s002530051373 ↗
42. Pronobesh Chattopadhyay, Subham Banerjee,Animesh Ghosh, Vijay Veer. 2013. Matrix type transdermal patch formulations. Patent no. 3033/DEL/2013.
43. Acute dermal irritation, sensitization, and acute toxicity studies of a transdermal patch for prophylaxis against (±) Anatoxin-a poisoning10.1177/1091581813489996 ↗
44. Evaluation of the mutagenic potential of a prophylactic transdermal patch by Ames test
45. Testing pressure sensitive adhesives
46. Bioadhesive properties of hydroxypropylcellulose topical films produced by hot-melt extrusion10.1016/S0168-3659(00)00365-5 ↗
47. Adhesive interactions between polymers and skin in transdermal delivery systems
48. Adhesive backing foil interactions affecting the elasticity, adhesion strength of laminates, and how to interpret these properties of branded transdermal patches10.1081/DDC-120015358 ↗
49. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat10.1016/S1526-5900(03)00618-7 ↗
50. System functionalityand physiochemical model of fentanyl transdermal system10.1016/0885-3924(92)90049-N ↗
51. An evaluation of bioequivalence of two 7-day 17b-estradiol transdermal delivery systems by anatomical site10.1177/009127002401382740 ↗
52. Dermalpenetration of fentanyl: inter- and intraindividual variations10.1046/j.1600-0773.2003.pto930508.x ↗
53. Potential and problems of developing transdermal patches for veterinary applications10.1016/S0169-409X(01)00157-0 ↗
54. Absorption characteristics of transdermally administered fentanyl10.1097/00000542-198906000-00008 ↗
55. Clinical considerations for transdermal delivery
56. The contact angle of water on viable human skin10.1016/0021-9797(68)90306-8 ↗
57. Medical-gradeacrylic adhesives for skin contact10.1002/app.1992.070450218 ↗
58. Adhesion-to-skin performance of a new transdermal nitroglycerin adhesive patch
59. Design and in vivo evaluation of an indapamide transdermal patch10.1016/j.ijpharm.2008.12.004 ↗
60. ISMP, Little patches… big problems, Institute for Safe Medication Practices: Medication Safety Alert!, 4(9) September (2005) 1–3.
61. Janssen, Dear Healthcare Professional letter; June (2005) 〈http://www.fda.gov/medwatch/SAFETY/2005/duragesic_ddl.pdf/〉
62. Peel
63. Effect of additives on the crystallization and the permeation of ketioprofen from adhesive matrix10.1016/S0378-5173(02)00017-0 ↗
64. Physical evaluation of a new patch made of a progestomimetic in a silicone matrix10.1016/S0378-5173(00)00357-4 ↗
65. The effect of flexible substrates on pressure-sensitive adhesive performance10.1016/S0143-7496(02)00018-0 ↗
66. Mechanism of oleic acid induced skin permeation enhancement in vivo in humans10.1016/0168-3659(95)00088-7 ↗
67. Patches, pumps and timed release: new ways to deliver drugs
68. Definition of a combination product (2005). “Title 21: food and drugs”. 21 CFR food and drugs CHAPTER I food and drug administration, Department of Health and Human Services Subchapter A- General Part 3-Product Jurisdiction. Available at 〈http://www.fda.gov/oc/ombudsman/part3 and 5.htm#21:1.0.1.1.3.1.31.2〉
69. FDA News (2007). “FDA approves neupro patch for treatment of early Parkinson's Disease”. FDA News, May 9, 2007. Available at 〈http://www.fda.gov/bbs/topics/NEWS/2007/NEW01631.html〉
70. Transdermal drug delivery: past progress, current status, and future prospects
71. Singh Somnath. (2005). An overview of transdermal drug delivery. Industry overview and deals. Drug delivery report autumn/winter 2005. Page(s):35-40. Available at: 〈http://www.drugdeliveryreport.com/articles/ddr_w2005_article06.pdf〉
72. Current status and future potential of transdermal drug delivery10.1038/nrd1304 ↗
73. Patent watch transdermal update
74. Dermal and transdermal drug delivery systems: current and future prospects10.1080/10717540500455975 ↗
75. Transdermal monitoring of glucose and other analytes using ultrasound10.1038/73213 ↗
76. A controlled-release microchip10.1038/16898 ↗
77. Biomaterials in drug delivery and tissue engineering: one laboratory's experience10.1021/ar9800993 ↗
78. A study of the adhesive–skin interface: correlation between adhesion and passage of a drug10.1016/S0378-5173(00)00369-0 ↗
79. Development of local patches containing melilot extract and ex vivo-in vivo evaluation of skin permeation10.1016/S0928-0987(99)00094-9 ↗
80. Water-activated, pH-controlled patch in transdermal administration of Timolol I: Preclinical tests10.1016/S0928-0987(00)00082-8 ↗
81. Permeation studies comparing cobra skin with human skin using nicotine transdermal patches10.1081/DDC-100101278 ↗
82. Transdermal delivery of a potent analgesic dihydroetorphine: kinetic analysis of skin permeation and analgesic effect in the hairless rat10.1211/0022357001777649 ↗
83. Enhancement of percutaneous absorption of ketoprofen: effect of vehicles and adhesive matrix10.1016/S0378-5173(98)00115-X ↗
84. Effect of vehicles and pressure-sensitive adhesives on the permeation of tacrine across hairless mouse skin10.1016/S0378-5173(99)00449-4 ↗
85. Development of a novel transdermal system design10.1016/0168-3659(87)90068-X ↗
86. Diffusion of drug in acrylic-type pressure-sensitive adhesive matrices on the drug diffusion10.1016/0168-3659(91)90132-W ↗
87. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol10.1016/S0378-5173(00)00494-4 ↗
88. Mechanism of transdermal controlled nitroglycerin administration III: control of skin-permeation rate and optimization10.3109/03639048509059864 ↗
89. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design10.1021/js950415w ↗
90. Nefopam containing transdermal-matrix patches: based on pressure sensitive adhesive polymers
91. Damodaran · Skin permeation of rosiglitazone from transdermal matrix patches · 2010 · 34 · 56
92. Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches